Advertisement covers The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011)

Switching From Atripla to Complera

January/February 2012

Now that the best-selling Atripla has a real competitor, an important question becomes, can people switch from Atripla to the new Complera?

While switching to a new and improved drug or regimen is common, there was a concern about switching here because of the way these drugs act in the body. The Sustiva in Atripla activates the protein (or enzyme) CYP34A. This is the same enzyme that the body uses to metabolize the Edurant in Complera. Sustiva has a long half-life and therefore drops the blood levels of Edurant; because there's too much metabolism of Edurant going on, the body eliminates it.

That interaction was recognized thanks to an earlier study that found a drop in Edurant blood levels of about 25% for approximately four weeks in volunteers switching from Sustiva to Edurant.

Fortunately, an HIV study presented at both ICAAC and IDSA has now shown that patients were able to maintain undetectable viral loads when switching from Atripla to Complera, out to three months. There was only a small temporary drop in Edurant blood levels.

At ICAAC, Dr. Tony Mills of Los Angeles made a poster presentation on the 49 patients switching from Atripla to Complera because of problems with tolerability. Atripla was their first HIV regimen and they had been taking it for at least three months (the average was 2.5 years). At week 12 after the switch, all 49 still had undetectable viral loads of less than 50 copies per mL.

The study did see lower than expected blood levels of Edurant at week one, but not at the other weeks in which bloodwork was collected (2, 4, 6, 8, and 12). The study concluded that "brief [Sustiva] inductive effects on [Edurant] metabolism may not be clinically relevant in suppressed patients [those with undetectable viral loads]," since all viral loads were undetectable at 12 weeks. The study also reported that Complera was well tolerated.

This article was provided by Positively Aware. It is a part of the publication Positively Aware. Visit Positively Aware's website to find out more about the publication.


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.